As an investment institution that has invested in high-quality companies such as Xiaomi, BOSS Zhipin, Huya Live, ByteDance, Yuanqi Forest, and Xiaohongshu, Gaorong Capital also has investments in the biopharmaceutical field. This article will provide a brief summary of the company's investment projects in the biopharmaceutical sector.

Gaorong Capital has participated in multiple rounds of financing (A+, A++, Pre-B) for 4b Technologies, being an existing shareholder of the company. 4b Technologies itself is a biotech company dedicated to developing innovative drugs for treating major neurological diseases.

The pipeline with the fastest progress at the company is FB1006, a potential drug for ALS (Amyotrophic Lateral Sclerosis), which is a product developed in collaboration with Insilico Medicine using AI.

BioGeometry is an AI large-molecule pharmaceutical company established in 2021. It owns TorchProtein, an open-source machine learning platform for large-molecule drug research and development. The company is committed to developing next-generation artificial intelligence technologies such as geometric deep learning and deep generative models for large-molecule drug discovery. BioGeometry is building two foundational platforms: AI-driven large-molecule drug design and high-throughput large-molecule drug wet-lab validation. Through a closed-loop integration of computational and experimental approaches, the company aims to accelerate candidate drug design and enhance the success rate of candidates in clinical stages.

The official website of the company's open-source sharing: https://torchprotein.ai/

Gaorong Capital participated in the angel round investment of Bivision Pharmaceuticals, which mainly focuses on developing theranostic TRT (Targeted Radionuclide Therapy). The concept of "theranostics" is derived from the integration of the words "diagnosis" and "therapy." Theranostic therapy involves the integration of a pair of highly correlated diagnostic and therapeutic agents that can be "seen" by medical imaging equipment. The molecular structures of the two agents are almost identical, with the only difference being the radionuclide they chelate. This theranostic approach aims to maximize the benefits of personalized treatment.

Currently, the company owns the J-Linker technology platform, which can rapidly and stably link highly selective and specific targeting ligands with particular radionuclides. Another highly valuable function is its flexible modulation of the physicochemical properties of molecules, significantly enhancing their drug-like properties. In December last year, the company’s fastest progressing clinical pipeline project, 177Lu-JH020002, completed the first subject enrollment and dosing.

Gaorong Capital participated in the Series B financing of Sironax (Beijing) Co., Ltd. Sironax, co-founded by Xiaodong Wang, co-founder of BeiGene, and Dr. Zhiyuan Zhang from the National Institute of Biological Sciences, adopts a pipeline strategy focused on developing products around key pathogenic signaling pathways. Since its establishment, the company has built a diversified R&D pipeline concentrating on the pathogenic mechanisms of aging-related degenerative diseases, including programmed cell death, neuroprotective pathways, and neuroinflammation.

Currently, the RIPK1 inhibitor is the fastest progressing pipeline in clinical trials by Sironax (Beijing) Co., Ltd., which has developed at least three pipelines related to RIPK1 inhibitors. The RIPK1 pathway plays a crucial regulatory role among inflammatory responses, apoptosis, and necroptosis signaling pathways, and the kinase structure of RIPK1 is highly suitable for developing specific pharmacological small-molecule inhibitors.

Therefore, the candidate indications are quite broad, such as neurodegenerative diseases like multiple sclerosis, ALS, and Alzheimer's disease, autoimmune diseases like lupus erythematosus, cancers like pancreatic tumors, and even COVID-19 falls within the scope of application.

Helixon is an AI-driven drug discovery company established in 2021, with Gaorong Capital participating in its Series A funding. The company has developed innovative algorithms for designing various small and large molecule drugs. Its technologies for analyzing patient genomic data include target discovery, as well as downstream efficacy analysis and clinical trial design, thereby accelerating the discovery, design, and optimization of new drugs, particularly large molecule drugs.

In 2022, the company announced the development of a groundbreaking predictive technology, OmegaFold. OmegaFold is the world's first algorithm that solves the existing computational prediction of three-dimensional structures, predicting the 3D structure of proteins from a single protein sequence alone—a milestone advancement in the history of computational biology.

In August last year, Gaorong Capital participated in the Pre-A round financing of DotBio. The company is a platform-based antibody technology company.

Adopt innovative therapeutic approaches to achieve ideal efficacy: Rapidly design multifunctional antibody prototypes to identify multifunctional antibodies with synergistic activity, optimal structure, and unique mechanisms of action.

DotBio adopts an approach that includes the use of the modular DotBody technology platform, Colony Filtration (CoFi), High-Temperature Colony Filtration (Hot-CoFi), high-throughput miniaturized testing, and data analysis to produce unique therapeutic molecules targeting disease factors both inside and outside of cells.

CASCADE was founded in 2017, and in February 2022, Gaorong Capital participated in its Pre-A+ round of financing.

The company is characterized by the original innovation and R&D of drugs targeting nuclear receptors and G protein-coupled receptors (GPCR). It focuses on significant unmet clinical needs such as metabolic diseases and inflammatory diseases, with an emphasis on the early discovery, drug development, and subsequent commercialization of innovative drugs. Currently, there are more than 10 targets with multiple candidate drugs under continuous development. The most advanced drug in the pipeline is CS0159, a non-bile acid full agonist targeting FXR. The company's selected indications primarily focus on metabolic diseases, which is a trending topic, as well as autoimmune diseases.

Hangzhou Andao Pharmaceutical Co., Ltd. was founded in 2014. Gao Rong Capital participated in the company's Series B financing in December 2021. The company's core technology lies in pipelines related to the body's hypoxia mechanism. The current pipelines are as follows:

Prolyl Hydroxylase (PH) Specific Inhibitor AND017 Can Mimic the Human Body's Response to Hypoxia in a Normoxic Environment. By Stabilizing HIF and Promoting the Specific Expression of Downstream Target Genes, It Increases Red Blood Cell Count for the Treatment of Anemia. Currently, Clinical Trials Are Being Conducted for Anemia Indications Caused by CKD (Chronic Kidney Disease) and Cancer.

AND019 is a third-generation selective estrogen receptor degrader (SERD) independently developed by Hangzhou Andao Pharmaceutical Co., Ltd. AND019 overcomes ER mutations through selective degradation of ER, thus avoiding drug resistance. Compared with the first two generations of SERDs, AND019 exhibits excellent efficacy and pharmacokinetic properties without significant gastrointestinal reactions.

The company has another ADC and clinical compound AND021 in preclinical development.

In September 2021, Gaorong Capital participated in the A+ round financing of MingMed, a company that has developed a relatively diversified pipeline. The current pipeline is divided into four categories: botulinum toxin, ophthalmic small molecules, tumor immunology, and pet immunology. Details are as follows:

For the indication of dry age-related macular degeneration in ophthalmology, QA102 mainly functions to improve compliance with related surgeries, while QA108 is a traditional Chinese medicine.

Botulinum toxin drugs are mainly targeted at the medical aesthetics market, with the indication of improving moderate to severe glabellar lines.

In the field of tumor immunology, the company has developed a novel small molecule HPK1 inhibitor, PRJ1-3024, for the treatment of advanced solid tumors.

In the pet immunization pipeline, MingMed has developed the small-molecule JAK inhibitor GGW101 for the treatment of canine pruritus, and another immune checkpoint inhibitor GGW102 for the treatment of feline infectious peritonitis (caused by feline coronavirus).

Abogen is an mRNA vaccine company that emerged during the COVID-19 pandemic, with Gaorong Capital participating in the company's Series C financing in August 2021. In addition to its COVID-19 vaccine, which has already been launched in India (under emergency authorization), the company is currently focusing primarily on its tumor vaccine pipeline, while other infectious disease and rare disease pipelines remain in the preclinical stage.

This is similar to BioNTech's approach, as the company currently has three pipelines in the IIT stage and one pipeline in Phase I clinical trials.